Skip to main content
B

Betta Pharmaceuticals Co.,Ltd — Investor Relations & Filings

Ticker · 300558 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,650 across all filing types
Latest filing 2026-04-22 Interim / Quarterly Rep…
Country CN China
Listing Shenzhen Stock Exchange 300558

About Betta Pharmaceuticals Co.,Ltd

https://www.bettapharma.com

Betta Pharmaceuticals Co.,Ltd. focuses on the research, development, and commercialization of innovative oncology medications. The organization specializes in targeted therapies, particularly for the treatment of lung cancer and other solid tumors. Its portfolio includes Icotinib, a small-molecule EGFR tyrosine kinase inhibitor, and Ensartinib, an ALK inhibitor designed for non-small cell lung cancer. The company operates a comprehensive R&D infrastructure dedicated to molecular biology, medicinal chemistry, and clinical development. By prioritizing precision medicine, the firm aims to deliver high-quality therapeutic solutions that address complex oncological challenges. Its pipeline encompasses a diverse range of candidates, including small molecules and biologics, aimed at improving patient outcomes through advanced scientific innovation.

Recent filings

Filing Released Lang Actions
2025年年度报告摘要
Interim / Quarterly Report Classification · 1% confidence The document is titled '贝达药业股份有限公司2025年年度报告摘要' (Betta Pharmaceuticals Co., Ltd. 2025 Annual Report Summary). It contains key financial highlights, business operations, product descriptions, and clinical trial data for the 2025 fiscal year. Although it is a 'summary' (摘要), it is a substantive financial document providing a comprehensive overview of the company's performance and business status for the year, which fits the definition of an Interim/Quarterly/Annual Report category (IR) in the context of financial reporting, as it contains actual financial data and analysis rather than just an announcement of a report. FY 2025
2026-04-22 Chinese
2025年度独立董事述职报告（JIANGNAN CAI-任期届满离任）
Governance Information Classification · 1% confidence The document is titled “2025年度独立董事述职报告” (2025 Independent Director’s Performance Report), detailing an independent director’s attendance, committee participation, key governance activities, and compliance with laws and company governance standards. It is not an earnings release or annual report, but a governance-related report on board structure and director duties. This matches the definition for Governance Information (CGR).
2026-04-22 Chinese
2025年度独立董事述职报告（汪炜-任期届满离任）
Governance Information Classification · 1% confidence The document is an annual performance report by an independent director, detailing attendance at board and committee meetings, oversight activities, compliance with governance rules, and the exercise of independent duties. It is not an earnings release, quarterly report, or a proxy solicitation, nor is it simply announcing publication of another report. Instead, it provides detailed governance-related information on board structure, committee work, internal control oversight, and the independent director’s duties. This aligns with the Governance Information category (CGR).
2026-04-22 Chinese
2025年度可持续发展报告
Environmental & Social Information Classification · 1% confidence The document is titled “2025年度可持续发展报告” (2025 Sustainability Report) and contains detailed ESG governance, environmental management, social responsibility, risk compliance and performance metrics. It references GRI Standards, UN SDGs and stock exchange ESG guidelines, and provides extensive narrative and quantitative data on environmental, social and governance topics. This matches the definition of an Environmental & Social Information report.
2026-04-22 Chinese
第五届董事会第二次会议决议公告
Board/Management Information Classification · 1% confidence The document is titled “第五届董事会第二次会议决议公告” and contains detailed minutes of a board of directors meeting, including convening details and resolutions passed by the board. It is not a full financial report, earnings release, or proxy solicitation, nor is it merely announcing the publication of another report. It clearly fits the category of board/management information, specifically a board meeting resolution announcement. Therefore, it should be classified under Board/Management Information (MANG).
2026-04-22 Chinese
2025年度募集资金存放与使用情况专项报告
Capital/Financing Update Classification · 1% confidence The document is Betta Pharma’s 2025 “募集资金存放与使用情况专项报告” — a detailed regulatory special report on the deposit, management and use of previously raised funds (IPO and private placement proceeds). It is not an earnings release or annual report, nor a simple release announcement. It is a required regulatory disclosure related to capital/financing activities (use‐of‐proceeds), fitting best under the “Capital/Financing Update” category.
2026-04-22 Chinese

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.